Abcam Announces Closing of Offering
October 26 2020 - 11:45AM
Abcam plc (AIM: ABC) ("
Abcam"), a global
leader in the supply of life science research tools, announces
today the closing of its offering of an aggregate of 10,287,000
American Depositary Shares ("
ADSs") representing
10,287,000 ordinary shares at a price of $17.50 per ADS, including
an aggregate of 1,341,782 American Depositary Shares representing
1,341,782 ordinary shares pursuant to the exercise of the
underwriters’ option to purchase additional ADSs, for aggregate
proceeds of approximately $180.0 million before deducting
underwriting discounts and commissions. Each ADS offered represents
one ordinary share of Abcam. The ADSs were offered in a registered
public offering in the United States (the
“
Offering”).
The ADSs began trading on the NASDAQ Global
Market under the ticker symbol "ABCM" on October 22, 2020. Abcam’s
ordinary shares are admitted to trading on the AIM market of the
London Stock Exchange under the symbol “ABC.”
Morgan Stanley and BofA Securities acted as the
lead book-running managers for the Offering. SVB Leerink acted as a
book-running manager, and Lazard and William Blair acted as
co-managers.
Application has been made for the 10,287,000
ordinary shares of Abcam underlying the ADSs to be issued in the
Offering to be admitted to trading on AIM, and it is expected that
admission will become effective and dealings in the ordinary shares
will commence at 8:00 a.m. (Greenwich Mean Time) on October 27,
2020.
Following the closing of the Offering, the
issued share capital of Abcam is 226,551,853 ordinary shares, and
this figure may be used by shareholders as a denominator for the
calculations by which they will determine if they are required to
notify their interest in, or change to their interest in, Abcam
under the Disclosure Guidance and Transparency Rules published by
the Financial Conduct Authority.
A registration statement relating to these
securities was declared effective by the Securities and Exchange
Commission on October 21, 2020. The Offering was made only by means
of a prospectus. Copies of the final prospectus relating to and
describing the terms of the Offering may be obtained from the
offices of Morgan Stanley, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, New York 10014; or from BofA
Securities, Attention: Prospectus Department, 200 North College
Street, 3rd Floor, Charlotte, North Carolina 28255-0001, or by
email at dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such
state or jurisdiction.
Forward Looking Statements
This press release contains forward-looking
statements. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding Abcam’s plans to conduct the Offering.
These forward-looking statements are based on
management’s current expectations. These statements are neither
promises nor guarantees but involve known and unknown risks,
uncertainties and other important factors that may cause Abcam’s
actual results, performance or achievements to be materially
different from its expectations expressed or implied by the
forward-looking statements, including, but not limited to, the
following: conditions in the U.S. capital markets, negative global
economic conditions, potential negative developments in the
COVID-19 pandemic, other negative developments in Abcam’s business
or unfavorable legislative or regulatory developments.
These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While Abcam may elect to update
such forward-looking statements at some point in the future, Abcam
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Abcam’s views as of any date subsequent
to the date of this press release.
For further
information, please contact:
Abcam |
+ 44 (0) 1223 696 000 |
James Staveley, Vice
President, Investor Relations |
|
|
|
Numis – Nominated
Advisor & Joint Corporate Broker |
+ 44 (0) 20 7260 1000 |
Garry Levin / Duncan Monteith
/ Huw Jeremy |
|
|
|
J.P. Morgan Cazenove –
Joint Corporate Broker |
+ 44 (0) 20 7742 4000 |
James Mitford / Hemant
Kapoor |
|
|
|
Morgan Stanley – Joint
Corporate Broker |
+ 44 (0) 207 425 8000 |
Tom Perry / Luka Kezic |
|
|
|
FTI
Consulting |
+ 44 (0) 20 3727
1000 |
Ben Atwell / Natalie
Garland-Collins |
|
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024